Dendritic-cell-based therapeutic vaccination against cancer.

Early clinical trials, in which over 1000 cancer patients received dendritic cell (DC) vaccines, tested different vaccine preparations, but they did not always induce sufficient acquired immunity or meet the expected level of tumor regressions. Current studies aim to improve the DC vaccine approach and capture the potential of these cells in order to gain access to lymphoid tissues and induce strong cell-mediated immunity. DC clinical trials are moving towards a more professional environment, in accordance with the latest quality standards. This explains the current need for innovative well designed trials with defined endpoints that induce robust anti-tumor immunity.

[1]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  V. Engelhard,et al.  Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Pardoll,et al.  Cancer immunotherapy: breaking the barriers to harvest the crop , 2004, Nature Medicine.

[4]  C. Figdor,et al.  Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.

[5]  H. Nisenbaum,et al.  Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Del Vecchio,et al.  Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination , 2004, Clinical Cancer Research.

[7]  Simon C Watkins,et al.  Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. , 2002, Journal of experimental therapeutics & oncology.

[8]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[9]  P. Coulie,et al.  Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide 1 , 2003, The Journal of Immunology.

[10]  Gabrielle T Belz,et al.  Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity , 2004, Nature Immunology.

[11]  V. Cerundolo,et al.  Dendritic cells: a journey from laboratory to clinic , 2004, Nature Immunology.

[12]  M. Dewhirst,et al.  Synergy between tumor immunotherapy and antiangiogenic therapy. , 2003, Blood.

[13]  J. Connolly,et al.  Mannose Receptor Targeting of Tumor Antigen pmel17 to Human Dendritic Cells Directs Anti-Melanoma T Cell Responses via Multiple HLA Molecules , 2004, The Journal of Immunology.

[14]  S. Vuk-Pavlović,et al.  Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma. , 2004, Cytotherapy.

[15]  E. Engleman.  Dendritic cell-based cancer immunotherapy. , 2003, Seminars in oncology.

[16]  Kris Thielemans,et al.  Generation of large numbers of dendritic cells in a closed system using Cell Factories. , 2002, Journal of immunological methods.

[17]  D. Speiser,et al.  Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination , 2004, Cancer Immunology, Immunotherapy.

[18]  G. Kvalheim,et al.  A Protocol for Generation of Clinical Grade mRNA‐Transfected Monocyte‐Derived Dendritic Cells for Cancer Vaccines , 2003, Scandinavian journal of immunology.

[19]  R. Steinman,et al.  Single Injection of CD34+ Progenitor-Derived Dendritic Cell Vaccine Can Lead to Induction of T-Cell Immunity in Patients With Stage IV Melanoma , 2003, Journal of immunotherapy.

[20]  P. Kalinski,et al.  Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. , 2001, Blood.

[21]  Donna Niedzwiecki,et al.  Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. , 2003, Cancer research.

[22]  R. Steinman,et al.  Detection and activation of human Vα24+ natural killer T cells using α-galactosyl ceramide-pulsed dendritic cells☆ , 2003 .

[23]  R. Steinman,et al.  Immunotherapy: Bewitched, Bothered, and Bewildered No More , 2004, Science.

[24]  J. Mulé,et al.  Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Adams,et al.  Manipulating dendritic cell biology for the active immunotherapy of cancer. , 2004, Blood.

[26]  M. Dullaers,et al.  Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  R. Steinman,et al.  The use of dendritic cells in cancer immunotherapy. , 2003, Current opinion in immunology.

[28]  A. Mackensen,et al.  Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. , 2004, Cancer research.

[29]  Mark M. Davis,et al.  Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Frank O. Nestle,et al.  Dendritic cells: On the move from bench to bedside , 2001, Nature Medicine.

[31]  B. Dörken,et al.  Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties , 2003, Cancer Immunology, Immunotherapy.

[32]  Sun-Min Lee,et al.  Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. , 2002, Journal of immunological methods.

[33]  D. Ridgway.  The First 1000 Dendritic Cell Vaccinees , 2003, Cancer investigation.

[34]  H. Wakasugi,et al.  Freeze-Thawing Procedures Have No Influence on the Phenotypic and Functional Development of Dendritic Cells Generated from Peripheral Blood CD14+ Monocytes , 2004, Journal of immunotherapy.

[35]  F. Nestle,et al.  Dendritic cell-based cancer therapy. , 2003, Current opinion in molecular therapeutics.

[36]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[37]  T. Juji,et al.  Therapeutic activation of Vα24^+Vβ11^+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity , 2004 .

[38]  Antonio Lanzavecchia,et al.  Regulation of Dendritic Cell Migration to the Draining Lymph Node , 2003, The Journal of experimental medicine.

[39]  R. Steinman,et al.  Prolonged IFN-γ–producing NKT response induced with α-galactosylceramide–loaded DCs , 2002, Nature Immunology.

[40]  D. Schadendorf,et al.  Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. , 2003, Blood.

[41]  F. Sallusto,et al.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells , 2000, Nature Immunology.

[42]  G. Schuler,et al.  Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy1 , 2004, The Journal of Immunology.

[43]  B. Ludewig,et al.  Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. , 2004, Journal of immunological methods.

[44]  C. Celluzzi,et al.  Dendritic cell culture: a simple closed culture system using ficoll, monocytes, and a table-top centrifuge. , 2003, Journal of hematotherapy & stem cell research.

[45]  S. H. van der Burg,et al.  Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes , 2002, Immunological reviews.

[46]  R. Blaese,et al.  Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. , 2003, Journal of neurosurgery.

[47]  M. Merad,et al.  Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. , 2004, The Journal of clinical investigation.

[48]  R. Steinman,et al.  Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma 1 , 2003, The Journal of Immunology.

[49]  J. Blay,et al.  Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. , 2004, The Journal of clinical investigation.

[50]  K. Black,et al.  Intratumoral Dendritic Cell Vaccination Elicits Potent Tumoricidal Immunity Against Malignant Glioma in Rats , 2003, Journal of immunotherapy.

[51]  C. Figdor,et al.  Phenotypical and Functional Characterization of Clinical Grade Dendritic Cells , 2002, Journal of immunotherapy.

[52]  D. Czerwinski,et al.  Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. , 2002, Blood.

[53]  C J Turtle,et al.  Dendritic cells in tumor immunology and immunotherapy. , 2004, Current drug targets.

[54]  P. Wernet,et al.  Clinical-Scale Generation of Dendritic Cells in a Closed System , 2003, Journal of immunotherapy.

[55]  S. Adams,et al.  Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R M Zinkernagel,et al.  Localization dose and time of antigens determine immune reactivity. , 2000, Seminars in immunology.

[57]  Özlem Türeci,et al.  Cascades of transcriptional induction during dendritic cell maturation revealed by genome‐wide expression analysis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  E. Gilboa,et al.  Injection of Immature Dendritic Cells into Adjuvant-Treated Skin Obviates the Need for Ex Vivo Maturation 1 , 2003, The Journal of Immunology.

[59]  M. Dhodapkar,et al.  Dendritic Cells and Immunotherapy for Cancer , 2003, International journal of hematology.

[60]  R. Dummer,et al.  Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. , 2003, Blood.

[61]  J. Fay,et al.  Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells , 2004, The Journal of experimental medicine.

[62]  C. Figdor,et al.  Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[63]  C. Turtle,et al.  Single step enrichment of blood dendritic cells by positive immunoselection. , 2003, Journal of immunological methods.

[64]  Ranjeny Thomas,et al.  Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen , 2002, Cancer Immunology, Immunotherapy.

[65]  R. Offringa,et al.  Revival of the regulatory T cell: new targets for drug development. , 2004, Drug discovery today.

[66]  R. Steinman,et al.  In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.

[67]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.